Janssen Inc. v. Pharmascience Inc., 2021 FC 5 (Abiraterone*)
Justice Phelan - 2021-01-06
Read full decision. Automatically generated summary:
Canadian Patent No. 2,661,422 is, and has always been, invalid, void and of no effect by reasons of obviousness/obvious to try as asserted by the Defendant and is to be removed from the Patent Register. Except for this declaration of invalidity, the making, constructing, using or selling of PMS-ABIRATERONE orally administered tablets containing 250 mg abiraterone acetate by Pharmascience Inc in accordance with its Abbreviated New Drug Submission No. 220472 would infringe the Asserted Claims.
Decision relates to:
- T-182-19 - JANSSEN INC. ET AL. v. PHARMASCIENCE INC.